MyRNA for Life

MyRNA for Life is a healthcare-focused subsidiary of Ludwig Enterprises that appears to be developing and marketing nutraceutical products positioned around genetic and inflammation-related health concepts. Public disclosures describe the company as a wholly owned subsidiary of Ludwig Enterprises alongside Precision Genomics, with an initial product branded MyRNA for Life licensed from Xikoz in late 2022. The product was described as a dietary supplement intended to modulate inflammatory conditions at the genetic level and was slated for launch in Q1 2023. Available public information suggests MyRNA for Life is more accurately characterized as a nutraceutical and precision-health commercialization vehicle than as a traditional drug-development biotech with a disclosed therapeutic pipeline. Evidence for clinical assets, regulatory-stage therapeutics, or named molecular drug programs is limited in public sources.